Biotechnology
Ascletis Presented Positive Phase I Clinical Data for Broad-Spectrum Antiviral Double Prodrug ASC10 at CROI 2023
--At the dosage of 800 mg ASC10, twice daily (BID), the exposure of the active drug, ASC10-A, is comparable to that of monupiravir's --ASC10 at 800 mg, BID is safe and well tolerated --Dosage of 800 mg ASC10, BID was selected for Phase IIa clinical trial for respiratory syncytial virus (RSV) inf...
2023-02-21 08:10
3766
iGene Laboratory Announces Launch of Whole Exome Sequencing Service
SINGAPORE, Feb. 21, 2023 /PRNewswire/ -- Singapore-based molecular diagnostics lab group iGene Laboratory announces the launch of FetalExome test service. FetalExome test is a whole exome sequencing (WES) test available for women with potentially complicated pregnancies. The test examines and a...
2023-02-21 08:00
2896
Angel Yeast Announces Plans to Beef up Supply and Innovation Capabilities In Response to Increasing Global Yeast Demand
YICHANG, China, Feb. 20, 2023 /PRNewswire/ -- The rising demand for yeast-based products over the past few years heralds steady growth of the market in the future, which also poses new challenges that require manufacturers to catalyze innovation and ramp up production and technology developmen...
2023-02-20 20:00
6896
Duoning Enters Partnership with BioAces to Expand Cell Analysis Portfolio
* Duoning obtained exclusive license from BioAces for its cell analysis portfolio * Through the partnership, the two companies will advance the development and commercialization of cell counters worldwide SHANGHAI, Feb. 20, 2023 /PRNewswire/ -- Shanghai Duoning Biotechnology Co., Ltd. ("Duoni...
2023-02-20 20:00
4706
Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU
Trial met primary and secondary endpoints and confirmed favourable safety and tolerability profile, indicating TLX250-CDx has the potential to become a new clinical standard in the identification and characterisation of clear cell renal cell carcinoma (ccRCC): * Primary endpoint met: Sensitivi...
2023-02-20 07:10
3257
Immuno Cure kick off Phase I Clinical Trial in Shenzhen
A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in PD-1-Enhanced DNA vaccines and immunotherapies,announced the ...
2023-02-16 20:36
7236
Alibaba Entrepreneurs Fund Launches JUMPSTARTER 2023 Global Pitch Competition
Newly added HKD1 million cash prize and a maximum total investment of up to USD5 million Encourage start-ups to integrate UN Sustainable Goals into businesses HONG KONG, Feb. 16, 2023 /PRNewswire/ -- Alibaba Hong Kong Entrepreneurs Fund ("AEF") today announced the JUMPSTARTER 2023 Global Pitch C...
2023-02-16 18:23
4312
Oral Presentation at APASL Annual Meeting 2023 Demonstrates ASC22, a Subcutaneous PD-L1 Antibody, Can Achieve Functional Cure of Chronic Hepatitis B
HANGZHOU and SHAOXING, China, Feb. 16, 2023 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") today announces that the oral presentation at the 2023 annual meeting of the Asian Pacific Association for the Study of the Liver ("APASL Annual Meeting 2023") demonstrates that ASC22 (Envafol...
2023-02-16 17:10
4105
Pharming provides update on EMA regulatory review of leniolisib for APDS in Europe
EMA Marketing Authorisation Application for leniolisib changed to standard review timetable LEIDEN, Netherlands, Feb. 16, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM) (Nasdaq: PHAR) announces that the European Medicines Agency's (EMA) Committ...
2023-02-16 14:00
3770
GNOMIX: An Australian Case Study to Democratise Clinical Applications of Genomics with MGI's DNBSEQ™ Platforms
BRISBANE, Australia, Feb. 16, 2023 /PRNewswire/ -- GNOMIX
2023-02-16 12:00
3327
Boan Biotech's Investigational Long-acting Anti-IL-4Rα Antibody BA2101 Administered for First Patient in Phase I Clinical Trial
YANTAI, China, Feb. 16, 2023 /PRNewswire/ -- Luye Pharma Group today announced that BA2101, an investigational anti-IL-4Rα antibody developed by its subsidiary Boan Biotech, has been administered for the first patient in a Phase I clinical trial. Recognized as a Class 1 innovative biological prod...
2023-02-16 08:15
4768
Innovent Announces First Patient Dosed in a Phase 3 Clinical Trial (CLEAR) of Picankibart (Anti-IL23p19 Monoclonal Antibody) in Patients with Moderate-to-Severe Plaque Psoriasis
ROCKVILLE, Md. and SUZHOU, China, Feb. 16, 2023 /PRNewswire/ -- Innovent Biologics, Group. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology ...
2023-02-16 08:00
4728
Tetracore Announces USDA Purchase of ASF and FMD Diagnostic Test Kits
ROCKVILLE, Md., Feb. 16, 2023 /PRNewswire/ -- Tetracore, Inc. (Tetracore®) is pleased to announce its partnership with the United States Department of Agriculture's (USDA) Animal and Plant Health Inspection Service (APHIS) to provide a stock of PCR kits for both African Swine Fever (ASF) and Foo...
2023-02-16 04:35
4538
Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
Randomized, double-blind, placebo-controlled study to evaluate efficacy of novel pan-GI prokinetic in patients with gastroparesis ROSCREA, Ireland and FREIBURG, Germany, Feb. 15, 2023 /PRNewswire/ -- Renexxion Ireland Limited, a private biopharmaceutical company committed to delivering innovativ...
2023-02-15 21:30
4096
Henlius Announces U.S. FDA Acceptance of Biologics License Application for Proposed Biosimilar Trastuzumab HLX02
* The first Chinese biosimilar approved in both China and the EU, and potentially to be approved in the U.S. - * HLX02 (trastuzumab for injection, trade name in China: HANQUYOU; trade name inEurope: Zercepac®; trade names in Australia: Tuzucip® and Trastucip®) has been approved in more than 3...
2023-02-15 16:49
4211
GILEAD TO PRESENT DATA AT APASL 2023 ON EFFECTIVE MODELS FOR MONITORING AND TREATING HEPATITIS C AND EFFICACY OF ANTIVIRAL TREATMENTS FOR HIV-1 AND HBV-COINFECTED ADULTS
- Study recommends a simplified strategy for baseline testing and minimal monitoring for treatment of hepatitis C virus (HCV) infection with DAA Therapies - Review of implementation science projects toward HCV Elimination by 2030 in Asia proved effective in improving patient outcomes - Efficacy ...
2023-02-15 10:00
3308
Innovent Announces First Participant Dosed in Phase 2 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Associated Ophthalmopathy
ROCKVILLE, Md. and SUZHOU, China, Feb. 15, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-02-15 08:00
5218
Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine
MELBOURNE, Australia, Feb. 15, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the successful completion of its joint research project conducted with Heidelberg University Hospital (UKHD) under the Research Cooperation Agreement announced inFebrua...
2023-02-15 04:51
2894
Eurofins Discovery Collaborating with Invasight on Cancer Therapies
SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Eurofins Discovery, the leading provider of products and services to the drug discovery industry, today announced its collaboration withInvasight, a Switzerland-based biotech developing cancer therapies. The collaboration focuses on advancing first-in-cla...
2023-02-15 00:10
2823
CJ Biomaterials Teams with Banila Co. to Develop New 100% Biobased Cosmetic Jar using Amorphous PHA
WOBURN, Mass., Feb. 14, 2023 /PRNewswire/ -- CJ Biomaterials, Inc., a division ofSouth Korea-based CJ CheilJedang and a primary producer of polyhydroxyalkanoates (PHAs), has produced the first cosmetic jar based on their amorphous PHA technology, under the tradename, PHACT™. The cosmetic jar was...
2023-02-14 22:00
3611
Week's Top Stories
Most Reposted
TotalEnergies ENEOS Extends Solar Partnership with Ceres in Indonesia
[Picked up by 316 media titles]
2026-06-08 10:16
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 303 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 296 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00Omni HR Launches Mino, the First AI Agent Built on Unified APAC HR Data
[Picked up by 284 media titles]
2026-06-08 09:00
Most Read
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
9362
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
8304
Tuniu Announces Unaudited First Quarter 2026 Financial Results
2026-06-05 18:00
8159
